PHAT
NASD Phathom Pharmaceuticals, Inc.$7.13 ↑ +0.05 (+0.71%) Trading Up from the previous close of $7.08, $0.07 below the day’s high of $7.20
- YTD change
- -57.02%
- vs 20-day SMA
- -10.20%
- vs 200-day SMA
- -37.69%
Price ranges
Price & Performance
-4.26 (-37.57%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 89.0% away from all-time highs of $64.54
- PHAT is down 57% since the beginning of the year
- PHAT is down 40% over the past 12 months
- PHAT is down 23% over the past 1 month
- 14% of all PHAT investors are betting against PHAT
PHAT reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -40.1%.
- Previous minute
- -$0.03
- Last hour
- +$0.05
- Last 5 days
- +0.71%
- vs 8-day SMA
- -2.02%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
